A. Early treatment is associated with less mortality. B. A goal of early therapeutic intervention is to minimize long-term disability. C. Escalation treatment algorithms concentrate all therapeutic efforts on the early phases of disease. D. Treatment of CIS may decrease conversion to clinically definite multiple sclerosis.

A. IFN-β is superior to glatiramer acetate for relapse reduction. B. Glatiramer acetate is superior to IFN-β for relapse reduction. C. IFN-β and glatiramer acetate together are better than either alone for relapse rate reduction. D. IFN-β and glatiramer acetate have similar rates of relapse reduction.

A. Glatiramer acetate B. Dimethyl fumarate C. Natalizumab D. Teriflunomide

A. Discontinue IFN-β1b and initiate fingolimod therapy B. Discontinue IFN-β1b and initiate natalizumab therapy C. Increase the dose of IFN-β1b D. Administer steroid therapy in conjunction with IFN-β1b

A. While MS disease-modifying treatments are expensive, MS is not one of the 4 conditions accounting for most of the double-digit increase in specialty drug expenditures in the United States. B. Specialty pharmacy programs for patients with MS do not show continued annual cost savings when the program is extended beyond 1 year. C. MS clinical management programs have demonstrated improved adherence and decreases in relapse rates. D. MS clinical management programs improve quality of life and work productivity and result in higher employment rates and annual incomes of patients with MS.